| Recruiting | First in Human Study of SIM0610 in Solid Tumors NCT07348211 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z NCT06929260 | AstraZeneca | Phase 1 |
| Recruiting | A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours NCT06868199 | LaNova Medicines Limited | Phase 1 / Phase 2 |
| Recruiting | Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors NCT06795412 | Pyxis Oncology, Inc | Phase 1 / Phase 2 |
| Recruiting | A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumour NCT06815575 | Race Oncology Ltd | Phase 1 |
| Terminated | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Mono NCT06599502 | AstraZeneca | Phase 1 |
| Recruiting | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer NCT06380816 | Cancer Research UK | Phase 1 / Phase 2 |
| Unknown | A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumou NCT05537051 | Biotheus Inc. | Phase 1 |
| Recruiting | A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours NCT05804526 | RemeGen Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of EBC-129 in Advanced Solid Tumours NCT05701527 | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | Phase 1 |
| Terminated | Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours NCT05920408 | Exscientia AI Limited | Phase 1 / Phase 2 |
| Completed | A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours NCT05508334 | RemeGen Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Soli NCT06927349 | Shandong Boan Biotechnology Co., Ltd | Phase 1 |
| Recruiting | First in Human Study of AZD9592 in Solid Tumors NCT05647122 | AstraZeneca | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese NCT05514132 | AstraZeneca | Phase 1 |
| Unknown | A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours NCT05154604 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 |
| Completed | A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therap NCT04907851 | Redx Pharma Ltd | Phase 2 |
| Terminated | A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours NCT04949425 | AstraZeneca | Phase 1 |
| Active Not Recruiting | Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or NCT04946968 | National Cancer Centre, Singapore | Phase 2 |
| Terminated | A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib NCT04959266 | AstraZeneca | Phase 1 |
| Completed | Capivasertib China PK Study NCT04742036 | AstraZeneca | Phase 1 |
| Completed | A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer NCT04564027 | AstraZeneca | Phase 2 |
| Completed | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours NCT04504669 | AstraZeneca | Phase 1 |
| Completed | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer NCT04434482 | Impact Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours NCT04462952 | AstraZeneca | Phase 1 |
| Unknown | Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours NCT03852823 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Terminated | A Phase 1 Study of [225Ac]-FPI-1434 Injection NCT03746431 | Fusion Pharmaceuticals Inc. | Phase 1 |
| Completed | Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours NCT03518606 | UNICANCER | Phase 1 / Phase 2 |
| Completed | AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and NCT03421353 | AstraZeneca | Phase 1 |
| Completed | BT1718 in Patients with Advanced Solid Tumours. NCT03486730 | Cancer Research UK | Phase 1 / Phase 2 |
| Completed | A Study of IMP4297 in Patients With Advanced Solid Tumors NCT03508011 | Impact Therapeutics, Inc. | Phase 1 |
| Completed | Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours NCT03101839 | AstraZeneca | Phase 1 |
| Completed | Extended Use of ModraDoc006/r NCT03150368 | Modra Pharmaceuticals | Phase 1 |
| Completed | The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors NCT03507543 | Impact Therapeutics, Inc. | Phase 1 |
| Completed | Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With NCT02617277 | AstraZeneca | Phase 1 |
| Completed | Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination Wit NCT02588105 | AstraZeneca | Phase 1 |
| Completed | A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. NCT02579226 | AstraZeneca | Phase 1 |
| Completed | The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid NCT02430311 | AstraZeneca | Phase 1 |
| Completed | PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib NCT02389842 | Royal Marsden NHS Foundation Trust | Phase 1 |
| Completed | Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumou NCT02341456 | AstraZeneca | Phase 1 |
| Completed | Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours NCT02042781 | Zucero Pty Ltd | Phase 1 |
| Terminated | Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours NCT01859351 | Heidelberg Pharma AG | Phase 1 |
| Terminated | A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours NCT01668550 | Cancer Research UK | Phase 1 |
| Completed | Phase I Study of AT13148, a Novel AGC Kinase Inhibitor NCT01585701 | Cancer Research UK | Phase 1 |
| Terminated | Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Pat NCT01581060 | Heidelberg Pharma AG | Phase 1 / Phase 2 |
| Terminated | Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours NCT01252095 | Zucero Pty Ltd | Phase 1 |
| Completed | Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumour NCT01163903 | University Health Network, Toronto | Phase 1 |
| Completed | A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion NCT01058538 | Philogen S.p.A. | Phase 1 / Phase 2 |
| Withdrawn | Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours NCT01194193 | AstraZeneca | Phase 1 |